Get IntellectAbility Dyskinesia Identification System: Condensed User Scale (DISCUS) 2011-2024

The DISCUS total score of 5 or above was associated significantly with physician TD diagnosis and the RD-TD intensity criterion. The psychometrically derived DISCUS cut-off score of 5 or above is a "red flag" that clinicians may use in monitoring individuals prescribed antipsychotic medication for TD.

Dyskinesia Identification System Condensed User Scale (DISCUS) are. presented for mentally ill and mentally retarded populations. A total score. cut-off was developed and tested against physician diagnosis and the Research. Diagnoses for Tardive Dyskinesia (RD-TD; Schooler & Kane, 1982).

Conclusions: The DISCUS is a reliable and valid unidimensional measure of experienced discrimination for use in global settings with similar properties to the longer DISC. It offers a brief assessment of experienced discrimination for use in clinical and research settings.

The DISCUS scale is a consistent and valid instrument to measure experienced and anticipated discrimination predominantly in personal and social relationships in global settings. The QUAD is a new measure of anticipated discrimination.

The DISCUS total score of 5 or above was associated significantly with physician TD diagnosis and the RD-TD intensity criterion. The psychometrically derived DISCUS cut-off score of 5 or above is a "red flag" that clinicians may use in monitoring individuals prescribed antipsychotic medication for TD.

The most commonly used rating scale for medication-induced dyskinesia is the Abnormal Involuntary Movement Scale (AIMS).

Description. The Dyskinesia Identification System: Condensed User Scale (DISCUS) was developed as a standardized rating scale to evaluate patients for signs of tardive dyskinesia. The DISCUS total score may be followed over time to assess a patient's response to different therapeutic interventions.

The Dyskinesia Identification System: Condensed User Scale (DISCUS) is another standardized rating scale for tardive dyskinesia (TD). The Extrapyramidal Symptom Rating Scale (ESRS) was developed to assess TD and other drug-induced movement disorders.